Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Particulate form
Reexamination Certificate
2005-07-05
2005-07-05
Page, Thurman K. (Department: 1615)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Particulate form
C424S489000, C424S494000, C424S495000, C424S484000, C424S486000, C424S464000, C424S468000, C424S451000, C424S457000
Reexamination Certificate
active
06913768
ABSTRACT:
A pharmaceutical composition comprises a once-a-day sustained release formulation of at least one amphetamine salt which provides mean plasma concentration profile aspects in human ADHD patients which are substantially the same as that provided by ADDERALL XR® type pulsatile formulations.
REFERENCES:
patent: 4049791 (1977-09-01), Cohen
patent: 4723958 (1988-02-01), Pope et al.
patent: 4728512 (1988-03-01), Mehta et al.
patent: 4765989 (1988-08-01), Wong et al.
patent: 4871549 (1989-10-01), Ueda et al.
patent: 4891230 (1990-01-01), Geoghegan et al.
patent: 4894240 (1990-01-01), Geoghegan et al.
patent: 4902516 (1990-02-01), Korsatko et al.
patent: 4917899 (1990-04-01), Geoghegan et al.
patent: 5002776 (1991-03-01), Geoghegan et al.
patent: 5011692 (1991-04-01), Fujioka et al.
patent: 5011694 (1991-04-01), Nuernberg et al.
patent: 5051262 (1991-09-01), Panoz et al.
patent: 5093200 (1992-03-01), Watanabe et al.
patent: 5156850 (1992-10-01), Wong et al.
patent: 5226902 (1993-07-01), Bae et al.
patent: 5229131 (1993-07-01), Amidon et al.
patent: 5232705 (1993-08-01), Wong et al.
patent: 5260068 (1993-11-01), Chen
patent: 5260069 (1993-11-01), Chen
patent: 5275819 (1994-01-01), Amer et al.
patent: 5308348 (1994-05-01), Balaban et al.
patent: 5312388 (1994-05-01), Wong et al.
patent: 5364620 (1994-11-01), Geoghegan et al.
patent: 5395628 (1995-03-01), Noda et al.
patent: 5407686 (1995-04-01), Patel et al.
patent: 5474786 (1995-12-01), Kotwal et al.
patent: 5496561 (1996-03-01), Okada et al.
patent: 5616345 (1997-04-01), Geoghegan et al.
patent: 5800836 (1998-09-01), Morella et al.
patent: 5824341 (1998-10-01), Segh et al.
patent: 5824342 (1998-10-01), Cherukuri et al.
patent: 5824343 (1998-10-01), Na et al.
patent: 5837284 (1998-11-01), Mehta et al.
patent: 5840329 (1998-11-01), Bai
patent: 5885616 (1999-03-01), Hsiao et al.
patent: 5885998 (1999-03-01), Bencherif et al.
patent: 5891474 (1999-04-01), Busetti et al.
patent: 5908850 (1999-06-01), Zeitlin et al.
patent: 5922736 (1999-07-01), Dariani et al.
patent: 5945123 (1999-08-01), Hermelin
patent: 6183780 (2001-02-01), Van Balken et al.
patent: 6214379 (2001-04-01), Hermelin
patent: 6217904 (2001-04-01), Midha et al.
patent: 6228398 (2001-05-01), Devane et al.
patent: 6322819 (2001-11-01), Burnside et al.
patent: 6340476 (2002-01-01), Midha et al.
patent: 6605300 (2003-08-01), Burnside et al.
patent: 0 212 747 (1987-03-01), None
patent: 768 512 (1957-02-01), None
patent: WO 87/00044 (1987-01-01), None
patent: WO 90/09168 (1990-08-01), None
patent: WO 97/03672 (1997-02-01), None
patent: WO 99/30694 (1999-06-01), None
patent: WO 99/51209 (1999-10-01), None
patent: WO 00/23055 (2000-04-01), None
patent: WO 00/35426 (2000-06-01), None
patent: WO 00/35450 (2000-06-01), None
patent: WO 0059481 (2000-10-01), None
US 6,034,101, 3/2000, Gupta et al. (withdrawn)
Walia et al., Preliminary Evaluation of an Aqueous Wax, Emulsion for Controlled-Release Coating, Pharm. Dev. Tech., vol. 3, No. 1, pp. 103-113 (1998).
Banker et al., Modern Pharmaceutics, eds., Marcel Dekker, Inc., New York, p. 350 (1996).
Gazzaniga et al., “Time-Dependent oral Delivery Systems for Colon Targeting,” S.T.P. Pharma Sciences 5(1):83-88 (1995).
Walia et al., “Preliminary Evaluation of An Aqueous Wax Emulsion for Controlled-Release Coating,” Pharmaceutical Development and Technology, 3(1):103-113 (1998).
Gazzaniga et al., “Oral Chronotopic Drug Delivery Systems: Achievement of Time And/Or Site Specificity,” Eur. J. Pharm. Biopharm, 40(4):246-250 (1994).
Pozzi et al., “The Time Clock System: A New Oral Dosage form for Fast and Complete release od Drug After a Predetermined Lag Time,” Journal of Controlled Release, 31:99-108 (1994).
Wilding et al., “Gastrointestinal Transit and Systemic Absorption of Captopril From A Pulsed-Release Formulation,” Pharmaceutical Research, 9 (5):654-657(1992).
Xin Xu et al., “Programmable Drug Delivery From An Erodible Association Polymer System,” Pharmaceutical Research, 10(8):1144-1152 (1993).
Conte et al., “Press-Coated tablets for Time-Programmed Release of Drugs,” Biomaterials, 14(13):1017-1023 (1993).
R. Gurny et al., Pulsatile Drug Delivery Current Applications and Future Trends, pp. 112-134, (1993).
Adderall XR, Package Insert, Oct. 2001.
Dexedrine, Spansule Capsules, Package Insert, Physicians' Desk Reference 1997.
Adderall, Package Insert, May 1996, Physicians' Desk Reference 1997.
K. S. Patrick et al., “Pharmacology of Methylphenidate, Amphetamine Enantiomers and Pemoline in Attention-Deficit . . . ” Human Psychopharmacology, vol. 12, pp. 527-546, 1997.
Lisa H. Brauer et al., “Acute Tolerance to Subjective but Not Cardiovascular Effects of d-Amphetamine in Normal, Healthy Men,” Journal of Clinical Psychopharmacology, vol. 16, No. 1, pp. 72-76, 1996.
William P. Melega et al., “Pharmacokinetic and Pharmacodynamic Analysis of the Actions of D-Amphetamine and D-Methamphetamine on the Dopamine Terminal,” The Journal of Pharmacology and Experimental Therapeutics, vol., 274, No. 1, pp, 90-96, 1995.
Peter Clausing et al., “Amphetamine Levels in Brain Microdialysate, Caudate/Putamen, Substantia Nigra and Plasma After Dosage That Produces Either Behavioral . . . ” The Journal of Pharmacology and Experimental Therapeutics, vol. 274, No. 2, pp. 614-621, 1995.
S.B. Sparber et al., “Amphetamine Cumulation and Tolerance Development: Concurrent and Opposing Phenomena,” Pharmacology Biochemistry & Behavior, vol. 20, pp, 415-424, 1984.
Burt Angrist et al., “Early Pharmacokinetics and Clinical Effects of Oral D-Amphetamine in Normal Subjects,” Biol Psychiatry, vol. 22, pp. 1357-1368, 1987..
Gerald L. Brown et al., Plasma Levels of d-Amphetamine in Hyperactive Children, PSYCHOPHARMACOLOGY, vol. 62, pp. 133-140, 1979.
Suk Han Wan et al., “Kinetics, Salivary Excretion of Amphetamine Isomers, and Effect of Urinary pH,” Clin. Pharmacol. Ther., pp. 585-590, May 1978.
Gerald L. Brown et al., “Plasma d-Amphetamine Absorption and Elimination in Hyperactive Children,” Psychopharmacology Bulletin, vol. 14, No. 3, pp. 33-35, 1978.
Excerpts from Feb. 2, 2005 Deposition of Beth A. Burnside inShire Laboratories Inc v Barr Laboratories, Inc., 03-CV-1219 and 03-CV-6632 (PKC), SDNY, pp. 1, 2 and 143-150.
Excerpts from Feb. 3, 2005 Deposition of Beth A Burnside inShire Laboratories Inc v Impax Laboratories Inc, 03-CV-1164 (GMS), D.Delaware, pp. 1-5 and 190-197.
Burnside Beth A.
Chang Rong-Kun
Couch Richard A.
Millen White Zelano & Branigan P.C.
Page Thurman K.
Sheikh Humera N.
Shire Laboratories Inc.
LandOfFree
Sustained release delivery of amphetamine salts does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Sustained release delivery of amphetamine salts, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Sustained release delivery of amphetamine salts will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3374570